Arbutus Biopharma Corporation (ABUS) Bundle
Understanding Arbutus Biopharma Corporation (ABUS) Revenue Streams
Understanding Arbutus Biopharma Corporation’s Revenue Streams
The total revenue for Arbutus Biopharma Corporation for the three months ended September 30, 2024, was $1,339,000, compared to $4,658,000 for the same period in 2023, indicating a decrease of $3,319,000 or 71.1%.
For the nine months ended September 30, 2024, the total revenue was $4,597,000, down from $15,996,000 in 2023, reflecting a decline of $11,399,000 or 71.3%.
Breakdown of Primary Revenue Sources
Revenue sources are primarily derived from collaborations and licenses, particularly royalties from sales of ONPATTRO and agreements with Qilu Pharmaceutical Co., Ltd. The revenue breakdown for the three months ended September 30, 2024, is as follows:
| Revenue Source | Q3 2024 (in thousands) | Q3 2023 (in thousands) | Percentage of Total Revenue Q3 2024 | Percentage of Total Revenue Q3 2023 |
|---|---|---|---|---|
| Royalties from ONPATTRO | $644 | $714 | 48% | 15% |
| Qilu Pharmaceutical Co., Ltd. | $123 | $3,221 | 9% | 69% |
| Non-cash royalty revenue from ONPATTRO | $572 | $723 | 43% | 16% |
| Total Revenue | $1,339 | $4,658 | 100% | 100% |
Year-over-Year Revenue Growth Rate
The year-over-year revenue growth rate for the three months ended September 30, 2024, shows a significant decline of 71.1% compared to the same quarter in 2023. For the nine-month period, the decline was 71.3%.
Contribution of Different Business Segments to Overall Revenue
For the nine months ended September 30, 2024, the contributions from various revenue segments are:
| Revenue Source | 9M 2024 (in thousands) | 9M 2023 (in thousands) | Percentage of Total Revenue 9M 2024 | Percentage of Total Revenue 9M 2023 |
|---|---|---|---|---|
| Royalties from ONPATTRO | $1,981 | $2,980 | 43% | 19% |
| Qilu Pharmaceutical Co., Ltd. | $880 | $10,349 | 19% | 65% |
| Non-cash royalty revenue from ONPATTRO | $1,736 | $2,667 | 38% | 17% |
| Total Revenue | $4,597 | $15,996 | 100% | 100% |
Analysis of Significant Changes in Revenue Streams
There was a notable decrease in revenue attributed to a decline in license revenue recognized due to the progress towards performance obligations with Qilu and lower sales of ONPATTRO. Specifically, revenue from Qilu Pharmaceutical fell by $9,469,000 or 91.5% year-over-year for the nine-month period.
The overall decrease in total revenue by $11.4 million for the nine months ended September 30, 2024, compared to the same period in 2023, was primarily due to these factors.
A Deep Dive into Arbutus Biopharma Corporation (ABUS) Profitability
A Deep Dive into Arbutus Biopharma Corporation's Profitability
Gross Profit Margin: For the nine months ended September 30, 2024, the company reported total revenue of $4,597,000 and operating expenses of $66,983,000, resulting in a gross profit margin of approximately -144.34%.
Operating Profit Margin: The loss from operations for the same period was ($62,386,000), leading to an operating profit margin of -135.44%.
Net Profit Margin: The net loss for the nine months ended September 30, 2024, was ($57,388,000), yielding a net profit margin of -124.36%.
Trends in Profitability Over Time
In comparison to the nine months ended September 30, 2023, where total revenue was $15,996,000 and net loss was ($53,537,000), the 2024 figures reflect a decrease in revenue by $11,399,000 or 71.14%. The net loss increased by $3,851,000 or 7.19%.
Comparison of Profitability Ratios with Industry Averages
The industry average for net profit margins in the biopharmaceutical sector typically ranges from -20% to -30%. The reported net profit margin of -124.36% indicates significantly lower profitability compared to industry norms.
Analysis of Operational Efficiency
Operational efficiency can be evaluated through several key metrics:
- Research and Development Expenses: For the nine months ended September 30, 2024, R&D expenses were $45,227,000, a decrease of $10,909,000 or 19.44% from $56,136,000 in 2023.
- General and Administrative Expenses: General and administrative costs remained stable at $17,396,000 compared to $17,374,000 in 2023.
- Gross Margin Trends: The gross margin has seen a decline, reflecting operational challenges and reduced revenue streams.
| Metric | 2024 (9 Months) | 2023 (9 Months) | Change |
|---|---|---|---|
| Total Revenue | $4,597,000 | $15,996,000 | -71.14% |
| Net Loss | ($57,388,000) | ($53,537,000) | 7.19% |
| R&D Expenses | $45,227,000 | $56,136,000 | -19.44% |
| G&A Expenses | $17,396,000 | $17,374,000 | 0.13% |
Debt vs. Equity: How Arbutus Biopharma Corporation (ABUS) Finances Its Growth
Debt vs. Equity: How Arbutus Biopharma Corporation Finances Its Growth
Overview of Debt Levels
As of September 30, 2024, Arbutus Biopharma Corporation reported no outstanding debt. The company has strategically maintained a debt-free status, which positions it favorably in terms of financial flexibility.
Debt-to-Equity Ratio
The company’s debt-to-equity ratio stands at 0.00, reflecting its absence of debt compared to its equity base. This ratio is significantly lower than the industry average, which typically ranges between 0.5 to 1.5 for biotechnology firms, indicating a conservative approach to financing its operations.
Recent Debt Issuances and Credit Ratings
There have been no recent debt issuances. The company has focused primarily on equity financing through sales of common shares. Credit ratings are not applicable as the company does not have any debt instruments rated by major credit rating agencies.
Equity Financing
In the nine months ended September 30, 2024, the company raised $44.1 million through the issuance of common shares under its Open Market Sale Agreement. Additionally, $6.1 million was raised from the exercise of stock options, contributing to a total of $50.6 million in financing activities during this period.
Table: Summary of Financing Activities
| Type of Financing | Amount (in millions) |
|---|---|
| Common Shares Issued (Open Market Sale Agreement) | $44.1 |
| Common Shares Issued (Exercise of Stock Options) | $6.1 |
| Total Financing Activities | $50.6 |
Balancing Debt and Equity Financing
The company has adopted a strategy favoring equity financing over debt to preserve cash flow and reduce financial risk. This approach allows Arbutus to allocate resources towards research and development without the burden of interest payments or debt obligations. As of September 30, 2024, the company held $130.8 million in cash, cash equivalents, and marketable securities, ensuring sufficient liquidity to support its ongoing operations and development projects.
In summary, Arbutus Biopharma Corporation's financial strategy reflects a strong preference for equity financing, resulting in a conservative debt profile that enhances its operational flexibility and positions it well for future growth opportunities while minimizing financial risk.
Assessing Arbutus Biopharma Corporation (ABUS) Liquidity
Assessing Arbutus Biopharma Corporation's Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
Current Assets: $130.8 million
Current Liabilities: $18.9 million
Current Ratio = Current Assets / Current Liabilities = $130.8 million / $18.9 million = 6.9
Quick Ratio: The quick ratio, excluding inventory, is:
Quick Assets (Cash + Cash Equivalents + Marketable Securities): $130.8 million
Quick Ratio = Quick Assets / Current Liabilities = $130.8 million / $18.9 million = 6.9
Analysis of Working Capital Trends
As of September 30, 2024, working capital is:
Working Capital = Current Assets - Current Liabilities = $130.8 million - $18.9 million = $111.9 million
Comparatively, as of December 31, 2023, working capital was:
Working Capital = Current Assets - Current Liabilities = $144.4 million - $22.5 million = $121.9 million
This indicates a decrease in working capital by $10 million over the period.
Cash Flow Statements Overview
The cash flow activities for the nine months ended September 30, 2024, are summarized below:
| Cash Flow Activity | Amount (in thousands) |
|---|---|
| Net Cash Used in Operating Activities | $(54,535) |
| Net Cash Provided by Investing Activities | $9,537 |
| Net Cash Provided by Financing Activities | $50,575 |
| Increase in Cash and Cash Equivalents | $5,561 |
| Cash and Cash Equivalents, End of Period | $31,846 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company reports:
- Cash, Cash Equivalents, and Investments: $130.8 million
- Outstanding Debt: $0
- Net Cash Burn Expected in 2024: Between $63 million and $67 million
The company believes it has sufficient cash resources to fund operations for at least the next 12 months .
Is Arbutus Biopharma Corporation (ABUS) Overvalued or Undervalued?
Valuation Analysis
Price-to-Earnings (P/E) Ratio
The current price-to-earnings (P/E) ratio is not applicable as the company reported a net loss of $57.388 million for the nine months ended September 30, 2024, resulting in a loss per share of $0.31.
Price-to-Book (P/B) Ratio
As of September 30, 2024, the book value per share is calculated as follows:
- Total stockholders' equity: $106.890 million
- Outstanding shares: 189.438 million
- Book value per share: $0.564 (calculated as $106.890 million / 189.438 million)
The current stock price is approximately $0.50, leading to a P/B ratio of 0.885.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
As of September 30, 2024:
- Enterprise Value (EV) = Market Capitalization + Total Debt - Cash and Cash Equivalents
- Market Capitalization (estimated stock price of $0.50 189.438 million shares): $94.719 million
- Total Debt: $0
- Cash and Cash Equivalents: $31.846 million
- EV = $94.719 million + $0 - $31.846 million = $62.873 million
For the nine months ended September 30, 2024, EBITDA is calculated as:
- Net Loss: $57.388 million
- Add back Non-Cash Items: $5.453 million
- EBITDA: ($57.388 million + $5.453 million) = -$51.935 million
The EV/EBITDA ratio is thus not applicable due to negative EBITDA.
Stock Price Trends
The stock price has shown volatility over the past year. The stock price was approximately $0.70 a year ago, declining to the current price of around $0.50.
Dividend Yield and Payout Ratios
The company does not currently pay dividends, and therefore, the dividend yield is 0%. The payout ratio is also not applicable as there are no earnings available for distribution.
Analyst Consensus on Stock Valuation
Analyst consensus ratings indicate a mix of recommendations:
- Buy: 2 analysts
- Hold: 5 analysts
- Sell: 1 analyst
The average target price set by analysts is approximately $0.60, suggesting a potential upside from the current market price.
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 0.885 |
| EV/EBITDA Ratio | N/A |
| Stock Price (Current) | $0.50 |
| Dividend Yield | 0% |
| Average Analyst Target Price | $0.60 |
Key Risks Facing Arbutus Biopharma Corporation (ABUS)
Key Risks Facing Arbutus Biopharma Corporation
Arbutus Biopharma Corporation faces several internal and external risks that could significantly impact its financial health and operational success. Below is a detailed examination of these risks.
Industry Competition
The biopharmaceutical industry is characterized by intense competition, with numerous companies developing therapies for hepatitis B virus (HBV) and other infectious diseases. The increasing number of competitors can lead to pricing pressures and decreased market share. For instance, the company has reported revenue from collaborations and licenses of only $2.86 million for the nine months ended September 30, 2024, a substantial decline from $13.33 million in the same period in 2023.
Regulatory Changes
Regulatory approvals are crucial for the development and commercialization of new therapies. The company's success is contingent upon obtaining necessary regulatory approvals, which can be delayed or denied due to stringent regulatory requirements. As of September 30, 2024, the company estimated a net cash burn between $63 million and $67 million for the year.
Market Conditions
Market conditions, including fluctuations in demand for therapeutic products and economic downturns, can adversely affect revenues. The total revenue decreased by $11.4 million for the nine months ended September 30, 2024, compared to the same period in 2023.
Operational Risks
Operational risks include disruptions in clinical trials and manufacturing processes. The company has recently incurred restructuring charges of $3.6 million due to workforce reductions aimed at streamlining operations. Additionally, the discontinuation of certain clinical programs has led to a reduction in research and development expenses by $10.9 million for the nine months ended September 30, 2024.
Financial Risks
Financial risks encompass liquidity challenges and reliance on funding. As of September 30, 2024, the company had cash, cash equivalents, and investments totaling $130.8 million. However, the company's ability to secure additional funding through equity or debt financing is uncertain, which may hinder its operational capacity and growth potential.
Strategic Risks
Strategic risks involve the company's decisions regarding product development and partnerships. The company has faced delays in product development, which can result in increased costs and missed market opportunities. The company reported a net loss of $57.4 million for the nine months ended September 30, 2024.
Mitigation Strategies
To address these risks, the company has implemented several mitigation strategies, including:
- Streamlining operations to reduce costs and enhance focus on core product candidates.
- Engaging in strategic partnerships to share the financial burden of research and development.
- Maintaining a strong cash position to ensure operational stability over the next 12 months.
| Risk Factor | Details | Financial Impact |
|---|---|---|
| Industry Competition | Intense competition in the biopharmaceutical market | Revenue decreased to $2.86 million from $13.33 million |
| Regulatory Changes | Delays in obtaining necessary approvals | Estimated net cash burn between $63 million and $67 million |
| Market Conditions | Fluctuations in demand for therapeutic products | Total revenue decreased by $11.4 million |
| Operational Risks | Disruptions in clinical trials and manufacturing | Restructuring charges of $3.6 million |
| Financial Risks | Liquidity challenges and reliance on funding | Cash position of $130.8 million |
| Strategic Risks | Delays in product development decisions | Net loss of $57.4 million |
Future Growth Prospects for Arbutus Biopharma Corporation (ABUS)
Future Growth Prospects for Arbutus Biopharma Corporation
Arbutus Biopharma Corporation is positioned for potential growth driven by several key factors in 2024. This chapter explores these growth opportunities, including product innovations, market expansions, strategic initiatives, and competitive advantages.
Key Growth Drivers
- Product Innovations: The company is advancing its lead candidates, imdusiran (AB-729) and AB-101. Imdusiran is currently in two Phase 2a combination clinical trials, demonstrating promising clinical data for chronic hepatitis B virus (cHBV) treatment.
- Market Expansions: Arbutus continues to explore global markets for its therapeutic solutions, focusing on regions with high unmet medical needs for cHBV treatments.
- Acquisitions: The potential for future partnerships or acquisitions to enhance its product pipeline remains a strategic focus, particularly in expanding its RNA-based therapeutic offerings.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, total revenue was reported at $4.6 million, a decrease from $16.0 million in the same period of 2023. This decline was primarily due to reduced license revenue from collaborations.
Projected net cash burn for 2024 is estimated between $63 million and $67 million, indicating a focus on sustaining operations while investing in product development. The company anticipates significant revenue growth as clinical trials advance and new licensing agreements are pursued.
Strategic Initiatives and Partnerships
Arbutus has initiated several strategic collaborations, including:
- Collaboration with Barinthus Biotherapeutics plc to evaluate imdusiran alongside Barinthus' VTP-300 in a clinical trial.
- Partnerships with Alnylam Pharmaceuticals and Acuitas Therapeutics for royalty entitlements related to ONPATTRO, providing ongoing revenue streams.
Competitive Advantages
The company holds several competitive advantages that position it well for future growth:
- Intellectual Property: Arbutus has a robust intellectual property portfolio, including patents related to lipid nanoparticle (LNP) technology, which is pivotal for RNA therapeutics.
- Clinical Expertise: The management team's extensive experience in virology enhances the company's ability to navigate the clinical development landscape effectively.
- Strong Financial Position: As of September 30, 2024, the company had cash, cash equivalents, and investments in marketable securities amounting to $130.8 million with no outstanding debt.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenue | $1.34 million | $4.66 million | Decreased by $3.32 million |
| Net Loss | $19.72 million | $20.10 million | Improved by $0.38 million |
| Cash and Cash Equivalents | $31.85 million | $17.53 million | Increased by $14.32 million |
Overall, Arbutus Biopharma Corporation's strategic focus on product innovation, market expansion, and strategic partnerships positions it favorably for future growth in the biopharmaceutical landscape. The financial metrics indicate a proactive approach to managing expenses while pursuing revenue opportunities in the evolving market for hepatitis B therapies.
Arbutus Biopharma Corporation (ABUS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Arbutus Biopharma Corporation (ABUS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Arbutus Biopharma Corporation (ABUS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Arbutus Biopharma Corporation (ABUS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.